APA (7th ed.) Citation

Cheng Fang, Chu Zhang, Wei-Qing Zhao, Wen-Wei Hu, Jun Wu, & Mei Ji. (2019). Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: A case report. BMC.

Chicago Style (17th ed.) Citation

Cheng Fang, Chu Zhang, Wei-Qing Zhao, Wen-Wei Hu, Jun Wu, and Mei Ji. Co-mutations of TP53 and KRAS Serve as Potential Biomarkers for Immune Checkpoint Blockade in Squamous-cell Non-small Cell Lung Cancer: A Case Report. BMC, 2019.

MLA (9th ed.) Citation

Cheng Fang, et al. Co-mutations of TP53 and KRAS Serve as Potential Biomarkers for Immune Checkpoint Blockade in Squamous-cell Non-small Cell Lung Cancer: A Case Report. BMC, 2019.